Cargando…

SG-APSIC1049: Immunogenicity of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in seropositive and seronegative adults

Objectives: Data comparing the immunogenicity of Sputnik-V and Sinopharm vaccines in seropositive and seronegative groups are lacking. We compared the immunogenicity of Sputnik-V (Gam-COVID-Vac) and Sinopharm (BBIBP-CorV) vaccines in seronegative and seropositive groups. Methods: In total, 60 adults...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stoma, Igor, Korsak, Katsiaryna, Voropaev, Evgenii, Osipkina, Olga, Kovalev, Aleksey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Covid-19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571176/ http://dx.doi.org/10.1017/ash.2023.15

Ejemplares similares

Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study
por: Stoma, Igor, et al.
Publicado: (2023)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
por: Hosseinzadeh, Rezvan, et al.
Publicado: (2022)

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 vaccine
por: Khalili, M.R., et al.
Publicado: (2022)

Cord blood antibodies following BBIBP‐CorV (Sinopharm) vaccination during pregnancy
por: Hantoushzadeh, Sedigheh, et al.
Publicado: (2023)

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
por: Zhang, Yaowen, et al.
Publicado: (2022)

Autoimmune encephalitis after BBIBP-CorV (Sinopharm) COVID-19 vaccination: a case report
por: Vences, Miguel A., et al.
Publicado: (2022)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
por: Ferenci, Tamás, et al.
Publicado: (2022)

Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study
por: Gómez de la Torre, Juan C., et al.
Publicado: (2022)

BBIBP-CorV: Hepatitis: case report
Publicado: (2022)

Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation
por: Rahbar, Maryam, et al.
Publicado: (2022)

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
por: Thonginnetra, Saraiorn, et al.
Publicado: (2022)

Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova
por: Ulinici, Mariana, et al.
Publicado: (2023)

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
por: Wang, Chao, et al.
Publicado: (2022)

Toxic epidermal necrosis following Sinopharm COVID‐19 vaccine (BBIBP‐CorV): A case report and literature review
por: Shakoei, Safoura, et al.
Publicado: (2022)

Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2023)

Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm)
por: Cvetkovic-Vega, Aleksandar, et al.
Publicado: (2023)

BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)

Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
por: Zaheri, Hamidreza, et al.
Publicado: (2022)

Upper extremity deep vein thrombosis following BBIBP‐CorV COVID‐19 vaccine (Sinopharm vaccine): A case report
por: Riazi, Ali, et al.
Publicado: (2023)

BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)

BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson syndrome: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson-syndrome: case report
Publicado: (2022)

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study
por: Safarnezhad Tameshkel, Fahimeh, et al.
Publicado: (2023)

BBIBP-CorV/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

BBIBP-CorV: Adult multisystem inflammatory syndrome: case report
Publicado: (2021)

BBIBP-CorV: Eye disorders and hypertension: 7 case reports
Publicado: (2021)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

BBIBP-CorV: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
por: Tang, Bo, et al.
Publicado: (2022)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)
por: Ismail AlHosani, Farida, et al.
Publicado: (2022)

Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Sinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
por: Abdelhafiz, Ahmed Samir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m1eeqcsj2luttarp8jn7e2vrvi